Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of clostridium difficile infection in mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 689-696

  Warren, Cirle A ^a   Van Opstal, Edward J ^a   Riggins, Mary S ^a   Li, Yuesheng ^a   Moore, John H ^a   Kolling, Glynis L ^a   Guerrant, Richard L ^a   Hoffman, Paul S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLISTIN; FIDAXOMICIN; GENTAMICIN; METRONIDAZOLE; NITAZOXANIDE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL OVERGROWTH; BACTEROIDES; CECUM; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; FECES ANALYSIS; HISTOPATHOLOGY; MICROBIAL COMMUNITY; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT INFECTION; TISSUE INJURY; TREATMENT DURATION; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEROIDES; CECUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DNA, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; INTESTINES; MALE; METRONIDAZOLE; MICE; MICE, INBRED C57BL; RECURRENCE; THIAZOLES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84872838994     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00877-12     Document Type: Article

References (30)

1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455. doi:10 .1086/651706.
2. Surawicz CM, Alexander J. 2011. Treatment of refractory and recurrent Clostridium difficile infection. Nat. Rev. Gastroenterol. Hepatol. 8:330-339. doi:10.1038/nrgastro.2011.59.
3. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. 2005. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40:1591-1597. doi:10.1086/430315.
4. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. 1992. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann. Intern. Med. 117:297-302.
5. Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. 2006. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 43:547-552. doi:10.1086 /506354.
6. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590. doi: 10.1086/430311.
7. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307.
8. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431. doi:10.1056 /NEJMoa0910812.
9. Garey KW, Jiang ZD, Bellard A, Dupont HL. 2008. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: An uncontrolled pilot study. J. Clin. Gastroenterol. doi:10.1097/MCG.0b013e31814a4e97.
10. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. 2007. Clostridium difficile colitis that fails conventional metronidazole therapy: Response to nitazoxanide. J. Antimicrob. Chemother. 59:705-710. doi:10.1093/jac/dkl553.
11. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficileassociated disease. Gastroenterology 135:1984-1992. doi:10.1053/j.gastro .2008.09.002.
12. Warren CA, OEvan Ballard TE, Kennedy A, Wang X, Riggins M, Olekhnovich I, Warthan M, Kolling GL, Guerrant RL, Macdonald TL, Hoffman PS. 2012. Amixicile, a novel inhibitor of pyruvate:ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. Antimicrob. Agents Chemother. 56:4103-4111. doi:10 .1128/AAC.00360-12.
13. Pawlowski SW, Calabrese G, Kolling GL, Freire R, Alcantara Warren C, Liu B, Sartor B, Guerrant RL. 2010. Murine model of Clostridium difficile infection using gnotobiotic aged C57Bl/6 mice and a BI strain. J. Infect. Dis. 202:1708-1712.
14. Guo X, Xia X, Tang R, Zhou J, Zhao H, Wang K. 2008. Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett. Appl. Microbiol. 47:367-373. doi:10.1111/j.1472-765X.2008.02408.x.
15. Salyers AA. 1984. Bacteroides of the human lower intestinal tract. Annu. Rev. Microbiol. 38:293-313. doi:10.1146/annurev.mi.38.100184.001453.
16. Herpers BL, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, Welte T, Kuijper EJ. 2009. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin. Infect. Dis. 48:1732-1735. doi:10.1086 /599224.
17. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. 2007. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44:846-848. doi:10.1086/511870.
18. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. 2009. Nitazoxanide versus vancomycin in Clostridium difficile infection: A randomized, double-blind study. Clin. Infect. Dis. 48:e41-e46. doi:10.1086 /596552.
19. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. 1999. Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20:43-50. doi:10 .1086/501553.
20. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. 2011. Mouse relapse model of Clostridium difficile infection. Infect. Immun. 79:2856-2864. doi:10.1128/IAI.01336-10.
21. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51:2716-2719. doi:10.1128/AAC. 01623-06.
22. Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH. 2009. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 63:520-525. doi:10.1093 /jac/dkn502.
23. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. 2012. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55(Suppl 2):S162-S169. doi:10.1093/cid/cis453.
24. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397.
25. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193. doi:10.1016/S0140-6736(00)03592-3.
26. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205. doi:10.1056/NEJMoa0907635.
27. Weiss K. 2009. Toxin-binding treatment for Clostridium difficile: A review including reports of studies with tolevamer. Int. J. Antimicrob. Agents 33:4-7.
28. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. 1997. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin. Infect. Dis. 25:729-732.
29. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. 2009. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53: 261-263. doi:10.1128/AAC.01443-07.
30. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficileinfected patients than does vancomycin. Microbiology 156:3354-3359. doi:10.1099/mic.0.042010-0.